Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + oxaliplatin + cetuximab
- Development stage
- Unknown
- Lead developer
- US Oncology Research
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen containing **docetaxel** (a taxoid that inhibits microtubule depolymerization), **oxaliplatin** (a platinum compound that forms DNA crosslinks and inhibits replication), and **cetuximab** (a monoclonal antibody against epidermal growth factor receptor (EGFR)). This protocol is used investigationally and in clinical trials for advanced **gastric adenocarcinoma** and **gastroesophageal junction adenocarcinoma**. Mechanistically, docetaxel and oxaliplatin act as cytotoxic agents while cetuximab targets EGFR to inhibit tumor cell proliferation and may help overcome resistance to chemotherapy.
- Other names
- DOCOX+C
02
Targets
Beyond the preview
Go deeper on docetaxel + oxaliplatin + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + oxaliplatin + cetuximab.